Stem Sellouts
By Jesse Reynolds,
TomPaine.com
| 07. 19. 2005
Recent developments—both technical and political —have once again brought stem cell research to the front pages of newspapers across the country. Sens. Tom Harkin, D-Iowa, and Arlen Specter, R-Pa., are the sponsors of a bill in the Senate that would largely undo President Bush’s restrictive federal funding policies. It’s already passed the House, and is scheduled for a Senate vote this month. But now conservatives are working to dilute support for it by introducing several competing bills that would fund stem cell research that does not destroy human embryos.
Progressives are inclined to react to these reports by strengthening their support of stem cell research as an effective wedge issue to split Republicans. But before we move ahead with simplistic calls for more funding and fewer restrictions, we should pay heed to troubles with California’s new stem cell research agency— and to the larger implications of biotech boosterism.
California’s Calamity
Last fall, Californians approved Proposition 71, which established the Institute for Regenerative Medicine to distribute $3 billion in stem cell research grants. Voters were swayed, with the help of a...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...